Pharma

Your Article Summary

See Latest Articles

Study shows GSK's novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight
GlaxoSmithKline, 06/09/09

New Phase II data presented at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

CCHIT Appoints Officers
HealthDataManagement, 12/18/09

 See all of Research & Development